Phialogics business idea is the result of a long and successful collaboration between A. Ernst, P. Oromi, M. Parnham, A. Weigert and A. v. Knethen. Each founding partner has a unique skill set with experience in industry and R&D that complement each other.
Andreas Ernst, acting CEO, CSO
International expert in generating affinity reagents with training from the labs of A. Skerra, A. Plückthun and S. Sidhu. With stints at Genentech, the University of Toronto, Medical Faculty of the Goethe University and the Fraunhofer IME-TMP, he has a 20+ years experience in running protein engineering projects in multinational teams.
Pascal Oromi, CBO
Hightech and Biotech industry veteran with more than 30 work experience at senior level. Part of management team at Gemalto that managed the M&A of SafeNet in 2014. In 2016, he left Gemalto at the position of Vice President Mobile Banking to become the managing director of Cenexi, a medical device CDMO and left this position in 2020 to apply his business expertise as advisor for start up companies.
Michael J. Parnham
Senior research manager for 30 years in medium sized (Nattermann, PLIVA) and multinational companies (Rhone-Poulenc, GSK). Currently serves as CSO of EpiEndo Pharmaceuticals. He helped to bring 7 projects including biologicals to clinical trials, 3 to registration and/or market approval (Ebselen, Epoetal, G-CSF/Nivestim).
15 years experience in inflammation and cancer research. As an author of more than 135 research papers in peer reviewed journals, he has an outstanding track record in animal and cutting-edge 3D in vitro disease models.
Andreas von Knethen
25 years experience in pre-clinical murine disease models of acute inflammation. Since Jan 2020 head of Experimental Anesthesiology in the Department of Anesthesiology, Intensive Care Medicine and Pain Therapy at the University Hospital Frankfurt/Main